IL13 and asthma: Similarly, subcutaneous tralokinumab (formerly CAT-354), an IL-13–neutralizing IgG4 MAb, improves lung function but not global asthma control scores in adults with moderate-to-severe uncontrolled asthma despite controller therapies.57